Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multisystem involvement. Although abnormalities in almost every aspect of the immune system have been found, the key defect is thought to result from a loss of self-tolerance to auto-antigens.
There is a strong female predilection in adults, with women affected 9-13 times more than males. In children, this ratio is reversed, and males are affected two to three times more often. While it can affect any age group, the peak age at onset around the 2nd to 4th decades, with 65% tend to present between the age of 16 and 65--i.e., during childbearing years.
Prevalence varies according to ethnicity with ratios as high as 1:500 to 1:1000 in Afro-Caribbeans and indigenous Australians, down to 1:2000 in Caucasians14-17.
Recent advances in diagnosis and treatment strategies has resulted in a survival improvement from 5 year survival at 40-50% in the 1950s up to a 10 year survival now estimated at 80-90%. Nevertheless, patients with SLE have a standardized mortality ratio of 3. Early deaths in disease course are usually due to active disease and immunosuppression while late deaths tend to arise from coronary atherosclerosis and SLE or treatment complications (e.g., chronic kidney disease and end-stage renal failure) 18.
The disease is sometimes classified according to early and late onset groups 8,9.
SLE can affect multiple components of the immune system, including the complement system, T-suppressor cells, and cytokine production. Emerging evidence has demonstrated a key player in the generation of autoantigens in SLE is the increase in generation (i.e., increased apoptosis) and/or decrease in clearance of apoptotic cell materials (i.e., decreased phagocytosis)13. It can result in a generation of autoantibodies, which can circulate for many years prior to the development of clinical SLE. The disease tends to have a relapsing and remitting course.
SLE has a myriad of clinical features and radiographic presentations that are discussed under individual subtopics:
- CNS manifestations of systemic lupus erythematosus (CNS lupus): neuropsychiatric events can occur in ~45% (range 14-75%) of cases 6,10
- renal manifestations of systemic lupus erythematosus
- gastrointestinal manifestations of systemic lupus erythematosus: there may be GI involvement in ~20% of cases 5
- thoracic manifestations of systemic lupus erythematosus
- cardiovascular manifestations of systemic lupus erythematosus
- musculoskeletal manifestations of systemic lupus erythematosus
Though pathogenesis is complex and not yet completely understood, there is a known genetic predisposition with multiple twin studies demonstrating higher concordance in monozygotic twins 19. Susceptibility likely results from a combination of multiple genetic and epigenetic aberrations with over 60 risk loci identified. Changes in gene expression contributing to SLE can be due to any and all of: sequence mutation, DNA methylation, histone modification, miRNAs and lncRNAs 20,21.
UV light (increased keratinocyte apoptosis), infection (via molecular mimicry and bacterial CpG motifs), smoking (OR 1.56 in current smokers, 1.23 in ex-smokers), environmental pollutants (silica) and intestinal dysbiosis are all known risk factors for SLE.
A number of culprit drugs have been involved in the development of drug-induced lupus which is a similar but separate disease entity characterized by generation of anti-dsDNA and anti-histone antibodies and a more protracted disease course resolving with withdrawal of the causative medicine. Drugs include chlorpromazine, diltiazem, hydralazine, IFN-alpha, isoniazid, methyldopa, minocycline, penicillamine, procainamide, quinidine.
TNF inhibitors can similarly induce autoantibodies in up to 70-80% of patients but rarely causes clinical lupus.
Almost all patients with SLE have a positive ANA (NPV >99%). Approximately 85% (range 70-98%) of patients test positive for anti-dsDNA antibodies 11, which can also be used to monitor disease activity. ~20% of Caucasians and ~35% of Asians/blacks test positive for anti-Smith antibodies 12 which are highly specific for SLE and tend to indicate a more serious disease course with renal and CNS involvement. Other antibodies include anti-Ro (neonatal lupus, subacute cutaneous lupus, Sjogren's), anti-La (neonatal lupus, Sjogren's), anti-U1RNP (myositis, Raynaud's), anti-ribosomal p (neuropsychiatric manifestations). Low complement C3 and C4 levels are often seen.
The diagnosis of SLE made be if four of eleven ACR (American College of Rheumatology) criteria are present, either serially or simultaneously 2. These criteria were initially published in 1982 but have been revised in 1997.
- malar rash: fixed, flat or raised, occurs over malar eminences and tends to spare the nasolabial folds.
- discoid rash: erythematous raised patches with adherent keratotic scaling and follicular plugging
- oral ulcers
- non-erosive arthritis: where there is involvement of two or more peripheral joints with tenderness, swelling or joint effusions; can occur in ~80% of cases 1
- pleuritis and/or pericarditis: present in ~35% (range 17-50%) of cases 1
- proteinuria: >0.5 grams/day
- hematological abnormality
- hemolytic anemia or
- leukopenia: <4000/mm3 on more than two occasions
- lymphopenia: <1500/mm3 on more than two occasions
- thrombocytopenia: <100,000/mm3 without any precipitant medications
- seizures or psychotic events in the absence of any underlying precipitating drugs or metabolic abnormalities
- immune abnormality on serology
- anti-DNA antibodies or
- anti-Sm antibodies or
- antiphospholipid antibodies (requires certain criteria)
- 27-42% of SLE patient can have the antiphospholipid antibody syndrome 1
- positive antinuclear antibodies
- 1. Lalani TA, Kanne JP, Hatfield GA et-al. Imaging findings in systemic lupus erythematosus. Radiographics. 24 (4): 1069-86. doi:10.1148/rg.244985082 - Pubmed citation
- 2. Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part I: CNS, cardiovascular, and thoracic manifestations. Clin Radiol. 2013;68 (2): 181-91. doi:10.1016/j.crad.2012.06.110 - Pubmed citation
- 3. Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part II: gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68 (2): 192-202. doi:10.1016/j.crad.2012.06.109 - Pubmed citation
- 4. Sanna G, Piga M, Terryberry JW et-al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000;9 (8): 573-83. Lupus (link) - Pubmed citation
- 5. Xu D, Yang H, Lai CC et-al. Clinical analysis of systemic lupus erythematosus with gastrointestinal manifestations. Lupus. 2010;19 (7): 866-9. doi:10.1177/0961203310365883 - Pubmed citation
- 6. Oku K, Atsumi T, Furukawa S et-al. Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology (Oxford). 2003;42 (6): 773-7. doi:10.1093/rheumatology/keg216 - Pubmed citation
- 7. Lim MK, Suh CH, Kim HJ et-al. Systemic lupus erythematosus: brain MR imaging and single-voxel hydrogen 1 MR spectroscopy. Radiology. 2000;217 (1): 43-9. Radiology (full text) - Pubmed citation
- 8. Braunstein EM, Weissman BN, Sosman JL et-al. Radiologic findings in late-onset systemic lupus erythematosus. AJR Am J Roentgenol. 1983;140 (3): 587-9. doi:10.2214/ajr.140.3.587 - Pubmed citation
- 9. Lalani S, Pope J, De leon F et-al. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J. Rheumatol. 2010;37 (1): 38-44. doi:10.3899/jrheum.080957 - Pubmed citation
- 10. Aisen AM, Gabrielsen TO, Mccune WJ. MR imaging of systemic lupus erythematosus involving the brain. AJR Am J Roentgenol. 1985;144 (5): 1027-31. doi:10.2214/ajr.144.5.1027 - Pubmed citation
- 11. Conti F, Ceccarelli F, Perricone C et-al. Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort. Mediators Inflamm. 06;2015: 328078. doi:10.1155/2015/328078 - Free text at pubmed - Pubmed citation
- 12. Systemic Lupus Erythematosus. Academic Press. ISBN:B00AXW76ZC. Read it at Google Books - Find it at Amazon
- 13. Choi, Jinyoung, Sang Taek Kim, and Joe Craft. "The pathogenesis of systemic lupus erythematosus—an update." Current opinion in immunology 24.6 (2012): 651-657. https://doi.org/10.1016/j.coi.2012.10.004
- 14. Johnson, Angela E., et al. "The prevalence and incidence of systemic lupus erythematosus in Birmingham, England." Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 38.4 (1995): 551-558. https://doi.org/10.1002/art.1780380415
- 15. Naleway, A. L., et al. "Epidemiology of systemic lupus erythematosus in rural Wisconsin." Lupus 14.10 (2005): 862-866. https://doi.org/10.1191%2F0961203305lu2182xx
- 16. Bossingham, D. "Systemic lupus erythematosus in the far north of Queensland." Lupus 12.4 (2003): 327-331. https://doi.org/10.1191%2F0961203303lu381xx
- 17. Segasothy, Murugasu, and Paddy A. Phillips. "Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: a comparative study." Lupus 10.6 (2001): 439-444. https://doi.org/10.1191%2F096120301678646191
- 18. Thomas, Guillemette, et al. "Mortality associated with systemic lupus erythematosus in France assessed by multiple‐cause‐of‐death analysis." Arthritis & rheumatology 66.9 (2014): 2503-2511. https://doi.org/10.1002/art.38731
- 19. Block, S. R., et al. "Studies of twins with systemic lupus erythematosus: a review of the literature and presentation of 12 additional sets." The American journal of medicine 59.4 (1975): 533-552. https://doi.org/10.1016/0002-9343(75)90261-2
- 20. Teruel, Maria, and Amr H. Sawalha. "Epigenetic variability in systemic lupus erythematosus: what we learned from genome-wide DNA methylation studies." Current rheumatology reports 19.6 (2017): 32. https://doi.org/10.1007/s11926-017-0657-5
- Long, Hai, et al. "The critical role of epigenetics in systemic lupus erythematosus and autoimmunity." Journal of autoimmunity 74 (2016): 118-138. https://doi.org/10.1016/j.jaut.2016.06.020